LifeMD (LFMD) Q2 FY26 earnings call

LifeMD's Q2 FY26 results reflect a strategic pivot towards quality revenue and diversified patient acquisition channels, moving beyond a reliance on paid media. While this transition led to a near-term adjusted EBITDA miss and a revised full-year outlook, the company reported strong underlying improvements in recurring revenue mix, gross margin, and operating costs. Management is focused on building longer-term patient relationships through branded therapies, pharmacy expansion, and strategic partnerships, aiming for a return to adjusted EBITDA profitability in Q3.